Immuneering Corporation Operating Lease Cost
Immuneering Corporation (IMRX) reported Operating Lease Cost of $373.18 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-05
- Immuneering Corporation operating lease, cost for the quarter ending 2026-06-30 was $186.59K, a 0.00% change year-over-year.
- Immuneering Corporation operating lease, cost for the quarter ending 2026-03-31 was $186.59K, a 0.00% change year-over-year.
- Immuneering Corporation operating lease, cost for the quarter ending 2025-12-31 was $186.59K, a 0.00% change year-over-year.
- Immuneering Corporation operating lease, cost for the quarter ending 2025-09-30 was $186.59K, a 0.00% change year-over-year.
- Immuneering Corporation operating lease, cost for fiscal 2025 was $746.36K, a 1.90% decline from fiscal 2024.
- Immuneering Corporation operating lease, cost for fiscal 2024 was $760.82K, a 13.23% decline from fiscal 2023.
- Immuneering Corporation operating lease, cost for fiscal 2023 was $876.79K, a 12.58% decline from fiscal 2022.
- Immuneering Corporation operating lease, cost for fiscal 2022 was $1.00M, a 523.47% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $186.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $373.18K 10-Q · filed 2026-08-05 | $559.77K derived: sum of 3 quarters · filed 2026-08-05 | $746.36K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $186.59K 10-Q · filed 2026-05-15 | $373.18K derived: sum of 2 quarters · filed 2026-05-15 | $559.77K derived: sum of 3 quarters · filed 2026-05-15 | $746.36K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $186.59K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $373.18K derived: sum of 2 quarters · filed 2026-03-06 | $559.77K derived: sum of 3 quarters · filed 2026-08-05 | $746.36K 10-K · filed 2026-03-06 |
| 2025-09-30 | $186.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $373.18K derived: sum of 2 quarters · filed 2026-08-05 | $559.77K 10-Q · filed 2025-11-12 | $746.36K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $186.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $373.18K 10-Q · filed 2026-08-05 | $559.77K derived: sum of 3 quarters · filed 2026-08-05 | $746.36K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $186.59K 10-Q · filed 2026-05-15 | $373.18K derived: sum of 2 quarters · filed 2026-05-15 | $559.77K derived: sum of 3 quarters · filed 2026-05-15 | $746.36K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $186.59K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $373.18K derived: sum of 2 quarters · filed 2026-03-06 | $559.77K derived: sum of 3 quarters · filed 2026-03-06 | $760.82K 10-K · filed 2026-03-06 |
| 2024-09-30 | $186.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $373.18K derived: sum of 2 quarters · filed 2025-11-12 | $574.23K 10-Q · filed 2025-11-12 | $775.28K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $186.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $387.64K 10-Q · filed 2025-08-13 | $588.69K derived: sum of 3 quarters · filed 2025-08-13 | $813.94K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $201.05K 10-Q · filed 2025-05-05 | $402.10K derived: sum of 2 quarters · filed 2025-05-05 | $627.35K derived: sum of 3 quarters · filed 2025-05-05 | $852.60K derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $201.05K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $426.30K derived: sum of 2 quarters · filed 2025-03-20 | $651.55K derived: sum of 3 quarters · filed 2025-03-20 | $876.79K 10-K · filed 2025-03-20 |
| 2023-09-30 | $225.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $450.50K derived: sum of 2 quarters · filed 2024-11-13 | $675.74K 10-Q · filed 2024-11-13 | $900.99K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $225.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $450.50K 10-Q · filed 2024-08-06 | $675.74K derived: sum of 3 quarters · filed 2024-08-06 | $926.07K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $225.25K 10-Q · filed 2024-05-07 | $450.50K derived: sum of 2 quarters · filed 2024-05-07 | $700.82K derived: sum of 3 quarters · filed 2024-05-07 | $963.69K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $225.25K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $475.58K derived: sum of 2 quarters · filed 2024-03-01 | $738.45K derived: sum of 3 quarters · filed 2024-03-01 | $1.00M 10-K · filed 2024-03-01 |
| 2022-09-30 | $250.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $513.20K derived: sum of 2 quarters · filed 2023-11-09 | $777.74K 10-Q · filed 2023-11-09 | $835.86K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $262.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $527.41K 10-Q · filed 2023-08-03 | $585.53K derived: sum of 3 quarters · filed 2023-08-03 | $619.78K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $264.54K 10-Q · filed 2023-05-04 | $322.66K derived: sum of 2 quarters · filed 2023-05-04 | $356.91K derived: sum of 3 quarters · filed 2023-05-04 | $391.17K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $58.12K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $92.37K derived: sum of 2 quarters · filed 2023-03-06 | $126.62K derived: sum of 3 quarters · filed 2023-03-06 | $160.87K 10-K · filed 2023-03-06 |
| 2021-09-30 | $34.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $68.50K derived: sum of 2 quarters · filed 2022-11-10 | $102.75K 10-Q · filed 2022-11-10 | $137.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $34.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $68.50K 10-Q · filed 2022-08-10 | $102.75K derived: sum of 3 quarters · filed 2022-08-10 | $113.55K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $34.25K 10-Q · filed 2022-05-10 | $68.50K derived: sum of 2 quarters · filed 2022-05-10 | $79.30K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $34.25K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $45.05K derived: sum of 2 quarters · filed 2022-03-10 | $66.65K 10-K · filed 2022-03-10 | |
| 2020-09-30 | $10.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $32.40K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $21.60K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |